SB1852: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
- 1Introduced (current step)
- 2Passed One Chamber
- 3Passed Both Chambers
- 4Became Law
Here is how to read this bill
Start with the summary
It says what the bill does in plain language. The official text is one tab over.
Check where it is
The status badge says how far it has gotten. The History tab lists every step.
Follow it
We will email you when it moves. You need a free account.
Tell someone who votes on it
Email or call the sponsor, or find your own representatives, from the actions panel.
Bill information
Summary
A bill to amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program.
Plain-language summary
This bill reauthorizes a federal demonstration program that prevents and treats sickle cell disease, a serious inherited blood disorder affecting mostly Black Americans. The program provides funding for research, tracking of cases, prevention efforts, and treatment services related to sickle cell disease and other heritable blood disorders. The bill amends the Public Health Service Act, which is the main law governing federal health programs. The bill was introduced in Congress and is currently awaiting review.
AI-generated summary
What can I do?
It's early in the process — messages to the sponsor and your representatives carry the most weight right now.
Contact Your Representatives
Calling or emailing is the most direct way to weigh in — offices tally constituent contacts.
Find Your RepresentativesShare This Bill
Sharing helps others in your district get informed and involved.
SB1852: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance,…